Citric Acid

Citric Acid

SCHEMBL989893

O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[K+].[K+].[K+].[Na+].[Na+].[Na+]

nearest known ligand 0.94

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BHRH2IMPA1

The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CA4 P22748 5/20 0.94
FAHD1 Q6P587 1/20 0.37
CASP1 P29466 1/20 0.36
FFAR3 O14843 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MEN1 O00255 1/20 0.32
LDHA P00338 1/20 0.32
BLM P54132 1/20 0.32
KMT2A Q03164 1/20 0.32
CA2 P00918 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Citric Acid SCHEMBL6690080 1.00 CA4 (0.94) CA4FAHD1CASP1FFAR3HDAC3
Citric Acid SCHEMBL6687136 1.00 CA4 (0.94) CA4FAHD1CASP1FFAR3HDAC3
Citric Acid SCHEMBL1303277 0.97 CA4 (0.90) CA4FAHD1CASP1FFAR3HDAC3
Citric Acid SCHEMBL8761101 0.97 CA4 (0.90) CA4FAHD1CASP1FFAR3HDAC3
Citric Acid SCHEMBL5328814 0.97 CA4 (0.90) CA4FAHD1CASP1FFAR3HDAC3
Citric Acid SCHEMBL23672268 0.97 CA4 (0.90) CA4FAHD1CASP1FFAR3HDAC3
Citric Acid SCHEMBL4818290 0.97 CA4 (0.90) CA4FAHD1CASP1FFAR3HDAC3
Citric Acid SCHEMBL5617378 0.97 CA4 (0.90) CA4FAHD1CASP1FFAR3HDAC3
Citric Acid SCHEMBL5617376 0.97 CA4 (0.90) CA4FAHD1CASP1FFAR3HDAC3
Citric Acid SCHEMBL1650869 0.97 CA4 (0.90) CA4FAHD1CASP1FFAR3HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119708547-A Metal-coated organic silicon resin microsphere and preparation method and application thereof 江苏涌新材料科技有限公司 2025-03-28 CN claimed
CN-119529328-A Metal-coated organosilicon elastomer microsphere, and preparation method and application thereof 江苏涌新材料科技有限公司 2025-02-28 CN claimed
US-20250000865-A1 COMPOUND FOR REDUCING URIC ACID LEVELS NEWSOARA BIOPHARMA CO., LTD. (CN) 2025-01-02 US claimed
CN-118268550-A Method for preparing high sphericity nano nickel powder 元颉新材料科技(浙江)有限公司 2024-07-02 CN claimed
CN-118079003-A Phosphodiesterase type 5 inhibitors for lowering uric acid levels and uses thereof 海南大学 2024-05-28 CN claimed
CN-114530598-B Nitrogen-oxygen-sulfur doped carbon negative electrode material and preparation method and application thereof 广东工业大学 2024-05-07 CN claimed
CN-115448289-B Oxygen-fluorine co-doped hard carbon anode material and preparation method and application thereof 广东工业大学 2023-12-01 CN claimed
CN-111315155-B Method for improving alignment degree of outer layer of mini LED PCB 惠州中京电子科技有限公司 2023-07-04 CN claimed
US-20230201386-A1 PRODUCING RADIOPHARMACEUTICAL COLD KITS WITHOUT LYOPHILIZATION THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA 2023-06-29 US claimed
CN-111957986-B Spherical nano copper powder and preparation method and application thereof 湖南泽宇新材料有限公司 2023-04-18 CN claimed
WO-2019192116-A1 CHARGED COMPOSITE MEMBRANE HAVING ELECTRICAL TOPOLOGY CHARACTERISTICS OF EXTRACELLULAR MATRIX AND PREPARATION METHOD THEREFOR 北京大学口腔医学院 2019-10-10 WO claimed
CN-108570692-A A method of by the leaded converting waste material containing lead battery be metallic lead 西安优庆商贸有限公司 2018-09-25 CN claimed
CN-104164443-B A kind of Dual-Luciferase detecting live body yeast cells UPR level monitors plasmid and structure thereof and application 东华大学 2016-11-16 CN claimed
CN-104164443-A Dual-luciferase monitoring plasmid for detecting living yeast cell UPR level, construction and application thereof NAT UNIV DONG HWA 2014-11-26 CN claimed
CN-101831668-B Clean wet-method solid-liquid two-phase electroreduction lead recovery method UNIV BEIJING CHEMICAL 2012-02-22 CN claimed
CN-101831668-A Clean wet-method solid-liquid two-phase electroreduction lead recovery method UNIV BEIJING CHEMICAL 2010-09-15 CN claimed
US-20040007469-A1 Forming three-dimensional multilayer structures by electroplating, ammonium citrate is included to improve anode dissolving, prevent deposits defect and short circuits, use low voltage; copper deposits has ductility, noncracking MEMGEN CORPORATION 2004-01-15 US claimed
US-5849268-A Oral compositions THE PROCTER & GAMBLE COMPANY (US) 1998-12-15 US claimed
US-5620679-A Oral compositions THE PROCTER & GAMBLE COMPANY (US) 1997-04-15 US claimed
WO-1995031174-A1 ORAL COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 1995-11-23 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250000865-A1 COMPOUND FOR REDUCING URIC ACID LEVELS PDE4A, PDE4B, PDE12 CA4 82/4885FAHD1 787/4885CASP1 930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.